Puma Biotech Announces Director, Officer, and Compensation Changes
Ticker: PBYI · Form: 8-K · Filed: May 9, 2025 · CIK: 1401667
| Field | Detail |
|---|---|
| Company | Puma Biotechnology, Inc. (PBYI) |
| Form Type | 8-K |
| Filed Date | May 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation, board-of-directors
TL;DR
Puma Biotech reshuffled its board and exec comp. New directors in, new comp plans out.
AI Summary
Puma Biotechnology, Inc. announced on May 8, 2025, changes related to its board of directors and executive compensation. Specifically, the company elected new directors and appointed new officers, alongside adjustments to their compensatory arrangements. These changes were filed with the SEC on May 9, 2025.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board and executive roles can indicate internal shifts that may affect strategic direction or operational stability.
Key Numbers
- 001-35703 — SEC File Number (Identifies the company's filing history with the SEC.)
- 77-0683487 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- PUMA BIOTECHNOLOGY, INC. (company) — Registrant
- May 8, 2025 (date) — Earliest event reported
- May 9, 2025 (date) — Filing date
- 10880 Wilshire Boulevard, Suite 2150 Los Angeles, California 90024 (address) — Principal executive offices
- INNOVATIVE ACQUISITIONS CORP (company) — Former company name
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors, but does not specify the names of newly elected or departing directors in the provided text.
Who are the newly appointed officers?
The filing mentions the appointment of certain officers but does not list their names or specific roles in the provided text.
What are the details of the compensatory arrangements for the officers?
The filing states that there were adjustments to compensatory arrangements for certain officers, but the specific details are not included in the provided text.
What is the exact date of the earliest event reported in this 8-K?
The earliest event reported is May 8, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 10880 Wilshire Boulevard, Suite 2150, Los Angeles, California 90024.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 9, 2025 regarding PUMA BIOTECHNOLOGY, INC. (PBYI).